Table 2.
Regimens and Efficacy of Immune Checkpoint Inhibitors in Patients with dMMR or MSI-H Tumors
| Regimen | Nivo 3 mg/kg q2w Ipi 1 mg/kg q6w24 |
Pembro 200 mg q3w25 | Nivo 3 mg/kg q2w Ipi 1 mg/kg q3w26,27 |
Nivo 3 mg/kg q2w19,20 | Pembro 200 mg q3w21 | Pembro 10 mg/kg q2w22 | Durva 10 mg/kg q2w23 | Durva 10 mg/kg q2w23 | |
|---|---|---|---|---|---|---|---|---|---|
| (NCT02227667) | (NCT01693562) | ||||||||
| Sample size | 45 | 153 | 119 | 74 | 63 | 40 | 11 | 36 | |
| Prior treatment lines | 0 | 0 | ≥1 | ≥1 | ≥1 | ≥2 | ≥2 | NA | |
| Best overall response, n (%) | |||||||||
| CR | 3 (7) | 17 (11) | 7 (6) | 7 (9) | 2 (3) | 5 (12) | NA | NA | |
| PR | 24 (53) | 50 (33) | 62 (52) | 18 (24) | 18 (29) | 16 (40) | NA | NA | |
| SD | 11 (24) | 32 (21) | 33 (28) | 23 (31) | 16 (25) | 12 (30) | NA | NA | |
| PD | 6 (13) | 45 (30) | 14 (12) | 22 (30) | 25 (40) | 4 (10) | NA | NA | |
| Not evaluable | 1 (2) | 9 (6) | 3 (3) | 4 (5) | 2 (3) | 3 (8) | NA | NA | |
| ORR | 27 (60) | 67 (44) | 69 (58) | 25 (33) | 20 (32) | 21 (52) | 3 (27) | 8 (22) | |
| CR + PR + SD ≥12 weeks | 38 (84) | 99 (65) | 96 (81) | 46 (62) | 36 (57) | 33 (82) | NA | NA | |
| PFS | NR | 16.5 months | NR | 6.6 months | 4.1 months | NR | 6 months | 6 months | |
| 1-year PFS, % | 77 | 55 | 71 | 44 | 41 | NA | 36 | 38 | |
| 2-year PFS, % | NA | 48 | 60 | NA | NA | 59 | NA | NA | |
| OS | NR | NA | NR | NR | NR | NR | NR | NR | |
| 1-year OS, % | 83 | NA | 85 | 72 | 76 | NA | NA | NA | |
| 2-year OS, % | NA | NA | 74 | NA | NA | 72 | NA | 54 | |
| TRAEs, n (%) | |||||||||
| Any | 35 (78) | 122 (80) | 87 (73) | 54 (73) | 40 (64) | NA | NA | NA | |
| Grades 3–5 | 7 (16) | 34 (22) | 37 (31) | 15 (20) | 7 (11) | NA | NA | NA | |
q(n)w, every (n) weeks. Anti-PD-1 antibody: Nivo (nivolumab), Pembro (pembrolizumab). Anti-PD-L1 antibody: Durva (durvalumab). Anti-CTLA-4 antibody: Ipi (ipilimumab). NR, not reached; NA, not available; TRAEs, treatment-related adverse events.